STING1 and central nervous system cancer: Given that insufficient immunogenicity and the immunosuppressive TME are the major hurdles limiting anti-glioma immunity, several immunotherapeutic strategies have been devised to increase glioma immunogenicity, including DC vaccines, STING agonists, oncolytic virus, and epigenetic modulators.